Achieve's Cash Rises To $201.5 Million Through Warrant Exercises Ahead Of FDA Resubmission
Operating spending increased, while a $6.9 million non-cash warrant gain helped narrow the quarterly loss.
Achieve Life Sciences, which is developing cytisinicline to help adults quit smoking or vaping, increased its cash and investments to $201.5 million at September 30 from $187.3 million at June 30, according to Tuesday's SEC earnings filing. The company attributed the increase primarily to investors exercising existing warrants—rights to buy shares—as it prepares to resubmit its FDA approval application.
Warrant Gain Softens The Loss
Achieve's third-quarter operating expenses rose to $20.5 million from $14.7 million a year earlier. Administrative costs reached $14.3 million, versus $9.4 million, while research and development spending increased to $6.2 million from $5.3 million.
The reported loss nevertheless narrowed to $12.1 million, or $0.11 per share, from $14.4 million, or $0.28 per share. A $6.9 million non-cash gain from changes in the value of warrant liabilities helped reduce that loss; the warrants were issued with a private placement in the second quarter of 2026.
For the first nine months, operating expenses totaled $49.4 million, compared with $40.1 million a year earlier. Administrative spending rose to $36.1 million from $21.0 million, while research and development fell to $13.3 million from $19.1 million. The nine-month net loss was $97.0 million, or $1.15 per share, versus $40.0 million, or $0.99 per share.
Ben Halladay, chief financial officer of AchieveRx, said his priority is "disciplined capital allocation that supports both our NDA resubmission and readiness for a potential U.S. launch in 2027" in the earnings release.
U.S. Manufacturing Supports Resubmission
Adare Pharma Solutions finished three commercial-scale batches for stability testing as Achieve moves finished cytisinicline manufacturing to the United States. Achieve expects to resubmit its FDA approval application in the fourth quarter of 2026.
Cytisinicline is an experimental oral tablet for nicotine dependence and has no FDA approval for any use. The smoking-cessation application draws on two completed late-stage trials and a long-term safety study. Achieve also completed a mid-stage vaping-cessation trial and met with the FDA afterward; that program has received Breakthrough Therapy designation and a Commissioner's National Priority Voucher.
The company identified sufficient stability data, addressing issues in the FDA's rejection letter, and possible manufacturing inspections as risks to its approval timetable. Its license and supply relationship with Sopharma covers territories outside Sopharma's markets, predominantly in Central and Eastern Europe; Achieve also cited its dispute with Sopharma AD among its risks.
A Quit Brand And Yearlong Data
Achieve adopted the AchieveRx brand Monday, calling itself The Quit Company, and began trading on Nasdaq as QUIT. Its commercialization team includes Halladay and Kaitlyn Tuson, senior vice president of marketing and communications, alongside previously announced appointments Ronald Dadino, senior vice president of CMC and supply chain, and Gloria Cosgrove, senior vice president of global quality.
In October, Achieve presented yearlong trial results at the CHEST 2026 Annual Meeting. The study enrolled 479 adults still smoking or vaping after a counseling-supported quit attempt in an earlier trial; participants who smoked had made a median of five previous quit attempts.
Four-week continuous abstinence reached 31.2% during weeks 49–52, versus 25.5% during weeks 9–12. At treatment's end, 39.4% of participants receiving cytisinicline for the first time had quit, compared with 27.8% of those previously treated with it. Achieve said the drug was generally well tolerated, and the independent Data Safety Monitoring Committee found no new safety signals.
Achieve anticipates potential FDA approval by the end of the second quarter of 2027, with a U.S. launch to follow only if approved.
Sources
- 8-K Filing — ACHIEVE LIFE SCIENCES, INC. (ACHV) — SEC EDGAR
- Exhibit achv-ex99_1.htm — ACHIEVE LIFE SCIENCES, INC. 8-K exhibit — SEC EDGAR
- AchieveRx Reports Third Quarter 2026 Financial Results and — globenewswire.com
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, — globenewswire.com